Aminocamptothecin in Treating Patients With Stomach Cancer or Cancer of the Esophagus

Completed · Phase 2

Conditions studied: Esophageal Cancer, Gastric Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of aminocamptothecin in treating patients with locally advanced, metastatic, or recurrent cancer of the stomach or esophagus.

Key facts

Study ID

NCT00003192

Run by

University of Chicago

People needed

15

Starts

1998-03-01

Expected to finish

2003-08-01

Last updated by the study team

2013-09-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Chicago Cancer Research Center — Chicago, Illinois, United States
• Louis A. Weiss Memorial Hospital — Chicago, Illinois, United States
• Cancer Care Specialists of Central Illinois, S.C. — Decatur, Illinois, United States
• Oncology/Hematology Associates of Central Illinois, P.C. — Peoria, Illinois, United States
• Central Illinois Hematology Oncology Center — Springfield, Illinois, United States
• Fort Wayne Medical Oncology and Hematology, Inc. — Fort Wayne, Indiana, United States
• Michiana Hematology/Oncology P.C. — South Bend, Indiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.